We investigated the role of bone morphogenetic proteins ( 4, BMP-6 and ID genes were found. We concluded that BMPs may have oncogenic properties and mediate ATRA resistance by a mechanism that involves ID genes.
Introduction
Acute promyelocytic leukemia (APL) is characterized by the accumulation of abnormal promyelocytes unable to differentiate into granulocytes and specific translocation t(15;17)(q22;q21) [1, 2] . Translocation results in the formation of PML/RARα (promyelocytic leukemia/retinoic acid receptor α) fusion gene that plays a central role in leukemogenesis of APL by blocking the function of RARα and PML proteins responsible for differentiation and apoptosis of APL cells [3] . All-trans retinoic acid (ATRA) is used for treatment of APL patients with high rate of complete remission when used alone or in combination with standard cytotoxic treatment [4] . Retinoic acid (RA) acts as morphogen through two subfamilies of nuclear receptors (RAR and RXR), ligand inducible transcription factors, in order to regulate the expression of genes containing retinoid response elements [5] . ATRA has been shown to induce terminal differentiation of APL cells by activation of RARα, and by inducing degradation of PML/RARα [2] . However, prolonged ATRA treatment often results in relapse due to the development of ATRA resistance by leukemic cells [4] . Although early studies suggested that an adaptive hypercatabolic response to pharmacological doses of ATRA is the principal mechanism of resistance, recent observations suggest that molecular disturbances in APL cells have a predominant role [6] .
Bone morphogenetic proteins (BMPs) are multi-functional growth factors that belong to the transforming growth factor β (TGF-β) superfamily. Besides their role in bone physiology, they also regulate proliferation, differentiation, morphogenesis and apoptosis of hematopoietic cells.
BMP-2 can induce hematopoietic environment after subcutaneous implantation and regulate apoptosis in various B-cell lines and primary myeloma cells [7] [8] [9] . BMP-4 has a crucial instructive role for the induction and formation of blood cell precursors [10] and induces formation of embryonic hematopoietic tissues [11] . BMP-6, produced by bone-marrow (BM) cells, participates in the regulation of proliferation, apoptosis and differentiation of B-cell lineage [12] . Dosen-Dahl et al showed that treatment with TGF-β or BMP-6 protects leukemic cells against chemotherapy-induced cell death and allow them to escape therapy [13] .
BMPs are known to exert their effect through two different types of serine-threonine kinase receptors known as receptors type I (BMP receptor (BMPR)IA, BMPRIB and activin receptor 4 (ActR)IA) and type 2 (BMPRII, ActRIIA and ActRIIB), and intracellular SMAD (small mothers against decapentaplegic) proteins, which play a central role in BMP signaling [14] . Important direct target of SMAD pathway is the gene family of DNA binding inhibitors (ID) [15] . ID genes encode a family of proteins that block basic helix-loop-helix transcription factors to bind to DNA, thus interrupting their regulatory role in many developmental and differentiation processes.
Different studies on human tumors proved their oncogenic properties in regulating cell-cycle progression, migration and invasiveness [15] [16] [17] [18] [19] .
Our previous study has shown that BMP-2, BMP-4 and BMP-7, and their receptors were strongly expressed in patients with APL, paralleled by the expression of PML/RARα oncogene. Absence of BMP expression correlated with clearance of the tumor molecular marker [20] . In this study, we aimed to investigate molecular mechanisms by which BMPs suppress differentiation of APL cells induced by ATRA, using myeloid cell lines NB4 and HL60, and primary samples from APL patients. Since RA/RAR pathway functionally interacts with BMP/SMAD signaling [21] , we proposed that BMP signal interfere with ATRA-induced differentiation of APL cells. Our findings may add to the understanding of the mechanisms of resistance to ATRA in APL patients.
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Materials and methods
Patient samples and cell lines
Human myeloid leukemia cell lines NB4 and HL60 (DSMZ cell line collection, Braunschweig, Germany) were grown in RPMI 1640 with 10% fetal calf serum (FCS) (Gibco, Invitrogen Ltd., Grand Island, NY, USA), 2 mM glutamax and 100 U/ml penicillin/streptomycin, in a 5% CO 2 [20] .
May-Grünwald Giemsa staining
Cytospin preparations for standard May-Grünwald Giemsa staining were made after ATRA treatment, as indicated in each experiment, to detect morphological changes associated with granulocyte differentiation (pale cytoplasm and mulitlobulated segmented nucleus) [23] . 6 
Flow-cytometric analysis
Myeloid leukemia cell lines NB4 and HL60 were analyzed by flow cytometry using a FACS [8] . 
Gene expression analysis
Statistics
All experiments were repeated at least three times. Gene expression triplicates in treated cell lines were expressed as mean ± standard deviation (SD) and compared using analysis of variance with Student-Newman-Keuls posthoc test. Gene expressions in primary samples were correlated to clinical data using rank correlation and Spearman's coefficient of rank correlation rho (ρ) with its 7 95% confidence interval. Statistical analysis was performed using MedCalc software-package (Mariakerke, Belgium). For all experiments, α-level was set at 0.05.
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Results
ATRA induced differentiation of NB4 and HL60 cell lines
We confirmed ATRA-induced differentiation of myeloid leukemia cell lines NB4 and HL60 by the expression of differentiation makers (CD11b/CD11c), and changes in cell proliferation and apoptosis. Differentiation was followed up to 4 days, with increase in the expression of CD11b
and CD11c 
BMPs suppressed differentiation of ATRA-treated NB4 and HL60 cell lines
Since our previous study on APL primary BM samples showed that treatment with ATRA was associated with the suppression of BMP expression [20] , we aimed to reveal the effect of BMPs on ATRA induced differentiation of NB4 cells as an in vitro model for APL. HL60 cell line, not bearing the specific t(15;17)(q22;q21) translocation, was used in addition to test if the BMP effect is PML/RARα specific. Cells were treated with the combination of ATRA and BMP-2, BMP-4 or BMP-6. BMP alone did not affect the expression of differentiation markers, but in 9 combination with ATRA reduced the percent of cells expressing CD11b and CD11c by 40 to 60% respectively, with stronger effect in NB4 cells (Figure 2A ). This effect was paralleled by expected morphological findings, i.e. more immature cell features upon combined treatment with BMP and ATRA compared to ATRA alone.
Our further aim was to evaluate BMP effect by analyzing the expression pattern of several intracellular molecules involved in proliferation, differentiation and apoptosis of APL cells.
Genes for ankyrin repeat and SOCS box protein 2 (Asb2) involved in RA-induced growth inhibition and myeloid differentiation, myeloid-specific transcription factors PU.1 and CCAATenhancer-binding proteins ε (C/EBPε), and ubiquitin-conjugating enzyme UBE2D3 [26, 27] were up-regulated in ATRA-treated groups in both cell lines. Expression of proto-oncogene Bcl-2, tyrosine-protein kinase cKit and distal-less homeobox gene 4 (Dlx4) associated with cell proliferation and tumorigenesis [28] , were decreased by ATRA treatment ( Figure 2B ). In general,
BMPs more effectively suppressed genes associated with cell differentiation, specifically PU.1, UBE2D3 and C/EBPε in NB4 cell line, compared with very weak or negligible effect on the restoration of proliferative/antiapoptotic oncogene expression.
Effect of BMP-2 and Noggin on promyelocytic cell lines treated with ATRA
Since we did not find significant difference in the effectiveness between tested BMPs, we assumed that their action was mediated by the same receptor complex (possible BMPRIA in combination with BMPRII or ActRIIB, according to the expression pattern presented at Figure   1C ). Therefore we used BMP-2 as a model to further study the role of BMPs in ATRAresistance. Again we confirmed that BMP-2 suppressed NB4 and HL60 ATRA-induced differentiation, assessed by CD11b/CD11c expression, but also revealed that the effect was BMPspecific since we were able to reverse BMP-mediated suppression of differentiation by NOG pretreatment ( Figure 3A ).
Further on, we aimed to identify molecular cross-road between BMP-signaling pathway and induction of genes that regulate promyelocyte differentiation. ID genes are well documented direct targets of BMP signaling [29] , which, at the same time, have important role in granulocyte 10 differentiation [30] as well as malignant transformation in several cell types [15] . ID1 and ID2
genes were induced by BMP-2 in both tested cell lines, but up-regulated by ATRA treatment only in NB4 cells. Combined treatment with BMP-2 and ATRA synergistically enhanced ID genes, particularly ID1 in both cell lines ( Figure 3B ). In addition, we hypothesized that more pronounced differentiation-suppressive effect of BMPs seen in NB4 cells compared with HL60
(approximately 50% suppression of CD11b expression in NB4 compared with 30% in HL60 cells, Figure 3A ) could be explained by constitutively higher expression of cKit, transcriptional target of BMPs with a role in hematopoietic cell survival and proliferation [31] . Nevertheless, cKit expression was highly suppressed by ATRA treatment, and not significantly affected by BMP-2. Combined treatment was able to only weakly increase the expression compared to ATRA alone ( Figure 3B ).
Correlation of PML/RARa oncogene expression and BMP-related molecules in APL patients
To Based on the expression pattern of BMP-related molecules, we further analyzed their correlations (specifically BMP-2, -4, -6, ID1, ID2, cKit, BAMBI, NOG, PU.1, UBE2D3, C/EBPε) with PML/RARα and RARα ( Table 1 ). The most significant positive correlations were found for PML/RARα and BMPs as well as their transcription target ID1, whereas significant negative correlations were found for BMP antagonist BAMBI and transcription factor PU.1, with the reciprocal correlations for RARα (Table 1) . Finally, expression of cKit [32] was in negative correlation with PML/RARα and positive with RARα. To better characterize the effect of BMPs on differentiation of APL cells, we used NB4 and HL60 cell lines. NB4 is RA sensitive APL cell line that harbors the specific t(15;17)
translocation. HL60, on the other hand, is a myeloblastic leukemia cell line that responds to RA but lacks t(15;17) translocation, suggesting that genetic alterations distinct from translocation involving RARα might generate APL-like phenotype [36] . In NB4 cells ATRA enhanced the expression of oncogene PML/RARα and total RARα, restoring RA-modulated myeloid differentiation [2, 37] . In parallel, ATRA reduced apoptotic/dead population of NB4 cells, which may be related to APL-differentiation syndrome seen upon ATRA treatment [38] . Syndrome is caused by the accumulation of mature granulocytes and can lead to a fatal outcome in APL patients. Increase in the percentage of cells in G 0 /G 1 cell-cycle phase is known to be caused by ATRA-induced over expression of ID1 and ID2 [33] . Among tested BMPs, NB4 expressed exclusively BMP-2 and HL60 BMP-4 (not shown), which act through the same receptor complexes, and both lines expressed BMP receptors, specifically BMPRIA, BMPRII and ActRIIB. BMPs and their receptors has been detected in BM in different pathological conditions [7, 8, 20] , suggesting an autocrine action.
BMP signaling pathway plays an important role in regulation of hematopoietic niches and stem cell population size maintaining BM homeostasis [39] as well as differentiation and growth of leukemic cells [9, 10, 12 ]. Therefore we proposed that BMP signal may target genes important 12 for granulocyte differentiation, causing promyelocyte resistance to ATRA. Several genes were identified to be rapidly induced by ATRA, i.e. SOCS box family gene Asb2, due to binding of RARα to Asb2 promoter [26] , and hematopoietic transcription factor PU.1, found to be suppressed in APL cell lines [27] . PU.1 shares some transcription targets with BMPs, such as ID2 [40] , and interacts with SMAD1 to enhance macrophage expression of interleukin 1β after BMP-6 treatment [41] . ATRA induction of PU.1 in cells harboring PML/RARα is mediated by upregulation of the C/EBP proteins, important for terminal granulocytic differentiation [27] . We observed that both PU.1 and C/EBPε were increased after treatment with ATRA, and repressed by BMPs, indicating that this could be one of the mechanisms involved in resistance to ATRAinduced differentiation [42] . C/EBP transcription factors interact with SMAD proteins leading to formation of C/EBP-SMAD complexes. Possible mechanism of C/EBP-SMAD antagonism could be the interference with C/EBP coactivator or competition for a common coactivator [43] . On the other hand BMPs could not restore the expression of proliferative genes highly suppressed by ATRA, including oncogene Bcl-2 and homebox gene Dlx4 [28, 44, 45] . Nevertheless, expression of cyclin D1 degradation enzyme UBE2D3, important for ATRA-mediated cell growth arrest [46] , was down regulated by addition of BMPs, possible causing an increase in the proportion of cells in the active cell-cycle phases (not shown).
Since it has been shown that SMAD3 interacts with RARα in a TGF-β dependent manner [47] , we proposed that simultaneous activation by ATRA and BMPs causes those two signals to interfere perpetuating immature APL phenotype. BMP signal during ATRA treatment synergizes in the induction of ID genes, which may lead to inhibition of differentiation and propose BMPs as oncogenic proteins. Despite the role in granulocyte differentiation, ID genes promote cell proliferation and malignant transformation in different cell types including hematopoietic cells, particularly myeloid [48] . cKit has also been involved in RA as well as BMP action [49, 50] . It has an important role in proliferation, differentiation and survival of normal hematopoietic and leukemic cells [49, 50] . We found negative correlation of cKit with oncogene PML/RARα and positive with RARα in APL BM samples, indicating its role in differentiation of APL cells upon ATRA treatment rather than proto-oncogenic property [32] . and total RARα was verified in BM and PBL at corresponding time-points by qPCR.
Expression of target genes was presented as RNA relative quantity and normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the endogenous control. nd, not determined. 
